Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Hematopoietic Stem Cell Mobilization
100%
CXCR4 Inhibitor
100%
Motixafortide
100%
Leukapheresis
77%
Hematopoietic Stem Cells
66%
Granulocyte Colony-stimulating Factor (G-CSF)
55%
CD34+ Cells
33%
Plerixafor
22%
Peripheral Blood Hematopoietic Stem Cells
22%
Allogeneic Donors
22%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
22%
Clinical Trials
11%
Hematological Malignancies
11%
Life-threatening
11%
Rapid Onset
11%
Chemotherapy
11%
Acute Myeloid Leukemia
11%
Bone Marrow
11%
Phase II Study
11%
Multiple Myeloma
11%
High Affinity
11%
Low Affinity
11%
Dose Effect
11%
Sickle Cell Disease
11%
Synthetic Peptides
11%
Institutional Review Board
11%
Informed Consent
11%
Healthy Volunteers
11%
C-X-C Chemokine Receptor Type 4 (CXCR4)
11%
AMD3100
11%
Blood Volume
11%
Dosing Strategy
11%
Bone Pain
11%
Dissociation Rate
11%
Mobilizing Agents
11%
Mobilization Regimen
11%
Toxicity Profile
11%
Unmet Needs
11%
Dose-ranging
11%
First Trial
11%
Subcutaneous Injection
11%
Cell Retention
11%
Common Agents
11%
HLA-matched Donor
11%
Studying up
11%
Chemokine Ligand 12 (CXCL12)
11%
2-parts
11%
Short-acting
11%
Multiple Patients
11%
Volunteer Patients
11%
Haploidentical Donor
11%
Sibling Donor
11%
HLA-identical
11%
Splenic Rupture
11%
CD34+ Cell Mobilization
11%
Vaso-occlusive
11%
Medicine and Dentistry
Stem Cell Mobilization
100%
Allogeneic Stem Cell Transplantation
100%
Hematopoietic Cell
100%
Leukapheresis
63%
Granulocyte Colony Stimulating Factor
45%
Plerixafor
27%
Cell Transplantation
18%
Oncology
18%
Clinical Trial
9%
Arm
9%
Hematologic Malignancy
9%
Receptor
9%
Acute Myeloid Leukemia
9%
Multiple Myeloma
9%
Informed Consent
9%
Volunteer
9%
Stromal Cell Derived Factor 1
9%
Bone Pain
9%
Subcutaneous Injection
9%
Sickle Cell
9%
Chemotherapy Agent
9%
Spleen Rupture
9%
Synthetic Peptide
9%
Immunology and Microbiology
Hematopoietic Cell
100%
CXCR4
100%
Allogeneic Stem Cell Transplantation
100%
Leukapheresis
53%
Granulocyte Colony-Stimulating Factor
38%
CD34
30%
Plerixafor
23%
Cell Transplantation
15%
Myeloid
7%
Normal Human
7%
Multiple Myeloma
7%
Sickle Cell
7%
Arm
7%
Stromal Cell-Derived Factor 1
7%
Pharmacology, Toxicology and Pharmaceutical Science
Granulocyte Colony Stimulating Factor
100%
Plerixafor
60%
Receptor
20%
Clinical Trial
20%
Hematologic Malignancy
20%
Multiple Myeloma
20%
Normal Human
20%
Acute Myeloid Leukemia
20%
Chemotherapy Agent
20%
Stromal Cell Derived Factor 1
20%
Bone Pain
20%
Subcutaneous Injection
20%
Synthetic Peptide
20%
Spleen Rupture
20%